Comprehensive genomic profiling (CGP) is becoming standard of care for cancer and allows pathology labs to consolidate individual biomarkers into a single NGS assay. It enables the assessment of all key biomarkers cited in guidelines and clinical trials using a minimal amount of formalin-fixed, paraffin-embedded (FFPE) tissue while increasing the chance of finding a positive biomarker for every sample.
Illumina’s TruSight Oncology 500 High-Throughput (TSO500 HT)assay enables labs to perform in-house CGP with scalability on a NovaSeq 6000 platform.
In this CellPress webinar, Brian Piening of Providence Cancer Center will discuss why his team decided to implement in-house CGP and will share analytical performance data from their TSO500_HT runs. He will also provide details of the center’s end-to-end workflow, including the data analysis flow and how they build their final reports.
Attendees of this webinar will learn about:
Technical Director, Clinical Genomics
Providence Cancer Center
Brian Piening is the Technical Director for Clinical Genomics in the Providence Healthcare System, focused on sequencing applications for clinical oncology, population health, and COVID-19.Dr. Piening is also on the faculty at the Earle A. Chiles Research Institute at Providence, where his research laboratory focuses on multi-omics and computational approaches in the development of better clinical biomarkers.Dr. Piening received his doctoral training at the University of Washington Fred Hutchinson Cancer Research Center and performed his postdoctoral training in the Department of Genetics at Stanford University.
Your email address is never shared with third parties.